PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) today announces its results for the year ended December 31, 2022, as well as its cash balance as of the first quarter...
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today...
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) today announces its half-yearly results for the six months ended June 30, 2022. The following information will be filed...
CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it...
Multiplex deletion of myeloid antigens CD33 and CLL-1 in human hematopoietic stem cells demonstrates potential of next-generation HSC transplants for...
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it...
Initial clinical data for Vor Bio’s engineered HSC candidate VOR33 expected in 2H 2022Data presented at Keystone Symposia demonstrates significant...
CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...
Akron BioProducts, a leading manufacturer of cGMP-compliant technologies for cell and gene therapy, and Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced an agreement...